HC Wainwright & Co. Maintains Buy on Insmed, Lowers Price Target to $230

Benzinga · 1d ago
HC Wainwright & Co. analyst Andrew S. Fein maintains Insmed (NASDAQ:INSM) with a Buy and lowers the price target from $240 to $230.